Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which may lead to uncontrolled immune activation and cytokine response in some. The pattern of pro-inflammatory cytokines is similar to that which has been observed to be involved in rheumatic diseases and target treatments. Viral arthritis is common with a wide variety in spectrum ranging from arthralgia to spurious and chronic arthritis. However, recent studies have demonstrated a correlation with endemic coronaviruses and increased risk of developing rheumatoid arthritis (RA). Cases are being identified that describe a post-COVID reactive; however, to date, no report has been published describing the onset of psoriasis and concomitant development of psoriatic arthritis after COVID-19 infection. We report an interesting case of psoriatic arthritis in a post-COVID-19 infection patient with review of the current literature.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128051 | PMC |
| http://dx.doi.org/10.1177/20406223221099333 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Updates on Recent Advances in the Therapy of Adult Psoriatic Disease.
Curr Rheumatol Rev
January 2025
University of Toronto, Psoriatic Arthritis Program, University Health Network, Toronto Western Hospital, Toronto, Ontario, Canada.
Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease with various joint and skin manifestations and multiple associated comorbidities. The management of PsA is important not only in controlling disease activity and preventing subsequent damage but also in improving the quality of life and reducing mortality. Over the years, numerous drugs have been introduced into the therapeutic armamentarium of the disease.
View Article and Find Full Text PDFAims: ultrasound (US) diagnosis of enthesitis is burdened of low specificity, especially when it is performed in patients with psoriasis (PsO) but without clinical psoriatic arthritis (PsA), because of mechanical, dysmetabolic and age-related concurrent enthesopatic changes. We propose a novel US score to quantify the cortical-entheseal bone remodeling burden of several peripheral entheses, aiming to improve the specificity of US for PsA-related enthesitis, and to evaluate its diagnostic value in PsO patients with subsequent diagnosis of psoriatic arthritis (PsO/PsA).
Methods: clinical and US data of 119 consecutive patients with moderate/severe PsO and nonspecific musculoskeletal symptoms, were included in this retrospective study.
Background: The percentage of Portuguese psoriasis patients with psoriatic arthritis is unknown but musculoskeletal complaints related to PsA affect up to a third of patients. Dermatologists can identify early PsA as skin symptoms often precede joint symptoms in 80% of patients. Efficient and easy to perform screening tools are needed to help dermatologists effectively discriminate between Pso and PsA patients.
View Article and Find Full Text PDFChinese herbal medicines and its active ingredient wogonin can improve immune inflammation in psoriatic arthritis.
Int Immunopharmacol
January 2025
Anhui University of Chinese Medicine, Hefei, Anhui 230012, China.
Objective: In China, Chinese herbal medicines (CHMs) have been widely used in the treatment of psoriatic arthritis (PsA), showing great therapeutic effects in clinical practice. However, due to the great heterogeneity of PsA and the diversity of CHM combination patterns, there is little high-level evidence-based medical research on the treatment of PsA with CHMs. This study aims to explore the beneficial effects of CHMs on the immune inflammation in PsA and its specific mechanism.
View Article and Find Full Text PDFVariability of Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) thresholds in psoriatic arthritis: data from the ReFlaP study.
Rheumatology (Oxford)
January 2025
Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.
Article Synopsis
- The study aimed to determine effective cutoff scores for the Psoriatic Arthritis Impact of Disease questionnaire (PsAID12) based on disease activity measures in patients with PsA.
- Using data from the ReFlaP study, researchers analyzed scores to define disease states such as remission and varying impact levels, employing statistical methods to establish these cutoffs.
- Results indicated that the PsAID12 score had high diagnostic performance against established benchmarks, but further validation and expert consensus are needed to confirm the proposed cutoffs for clinical use.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!